Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBLP
- Development stage
- Preclinical
- Lead developer
- ReBio Technologies
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravitreal
01
Overview
RBLP is a sustained-release formulation of latanoprost being developed by ReBio Technologies for the treatment of mild-to-moderate primary open-angle glaucoma. It utilizes the proprietary SiSu® technology platform, a resorbable polymer system designed for long-term, steady release of therapeutics within the eye. Administered via intravitreal injection approximately twice a year, RBLP aims to improve patient compliance and maintain consistent intraocular pressure reduction compared to traditional daily eye drops. The polymer scaffold is designed to safely dissolve once the drug release is complete, addressing the challenges of frequent dosing in chronic ocular conditions.
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on RBLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBLP.